Processa Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Net Loss Per Common Share, Disclosure: Schedule of Earnings Per Share (Tables)

Net Loss Per Common Share, Disclosure: Schedule of Earnings Per Share (Tables)

12 Months Ended

Dec. 31, 2015

	For the year ended December 31, 2015		For the year ended December 31, 2014
Net loss from continuing operations	$	(2,982,920)	$	(3,685,601)
Net loss from discontinued operations		(371,307)		(840,649)
Net loss		(3,354,227)		(4,526,250)
Basic and diluted:
Preferred stock cumulative dividend - Series B ⁽¹⁾		--		(62,227)
Preferred stock cumulative dividend - Series C		--		2,200
Preferred stock cumulative dividend - Series D		42,942		230,542
Deemed dividend - inducement premium		--		1,332,376
Income applicable to preferred stockholders		42,942		1,502,891
Net loss applicable to common stockholders	$	(3,397,169)	$	(6,029,141)

(1) Upon conversion of the Series B preferred stock into common stock, the holders of the Series B preferred stock were no longer entitled to the dividends recorded in the adjustment to net loss applicable to common shareholders in prior periods. As a result, prior year reported dividends were adjusted downward to reflect this release of accumulated dividends.